Idiopathic pulmonary fibrosis: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• AKT 0
• PI3K 0
• mTOR 0
• AMPK 0
• TP53 0
• HIF-1 0
• NRF2 0
• MAPK 0
• STAT3 0
• MMP-9 0
• PPAR 0
• YAP 0
• IL-1 0
• PDE4 0
• BCL-2 0
• HMGB1 1
• IL-17 0
• JAK 0
• MEK 0
• METTL3 0
• NLRP3 0
• PTEN 0
• STING 0
• TLR4 0
• CTNNB1 0
• EGFR 0
• ERK 0
• HSP90 0
• PD-1 0
• PD-L1 0
• PINK1 0
• ACE2 0
• APOE 0
• ATM 0
• BDNF 0
• BRD4 0
• CD20 0
• CD47 0
• CDKN2A 0
• COX-2 0
• CSF1R 0
• CXCR4 0
• DLL3 0
• ESR1 0
• FGFR 0
• GLP-1 0
• GPX4 0
• HDAC 0
• IL-6 0
• JNK 0
• NTRK 0
• PDGFR 0
• PKM2 0
• SIRT1 0
• STK11 0
• TERT 0
• TFEB 0
• TNF 0
• TSLP 0
• VEGF 0

24 of 863 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NHLBI · R44

  A Novel Water-Soluble, Orally-Active Peptide Therapeutic for Interstitial Lung Disease Derived from the Caveolin-1 Scaffolding Domain

  Fibrotherapeutics, Inc.· Charleston, United States· US$920,624 awarded in fiscal year 2026· until May 2028

• NIH NHLBI · UG3

  1/2 Efficacy and Safety of Obinutuzumab in Connective Tissue Disease-Related Interstitial Lung Disease

  National Jewish Health· Denver, United States· US$1,000,770 awarded in fiscal year 2026· until May 2031

• NIH NHLBI · U24

  2/2 Efficacy and Safety of Obinutuzumab in Connective Tissue Disease-Related Interstitial Lung Disease

  Johns Hopkins University· Baltimore, United States· US$1,446,483 awarded in fiscal year 2026· until May 2031

• NIH NIAMS · K23

  Quantitative chest imaging and serum proteomics in patients with systemic autoimmune rheumatic disease-associated interstitial lung disease

  Brigham and Women's Hospital· Boston, United States· US$172,470 awarded in fiscal year 2026· until Aug 2031

• NIH NIAMS · R01

  Defining the role of SLC9A1 in fibroblast pathobiology during Systemic Sclerosis and Systemic Sclerosis-associated Interstitial Lung Disease

  University of Maryland Baltimore· Baltimore, United States· US$608,966 awarded in fiscal year 2026· until Jul 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  COMPrehensive framework for dAta-driven chemical teSting Solutions (COMPASS)

  Tampereen Korkeakoulusaatio Sr· Tampere, Finland· EU contribution €242,117· until Aug 2029· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Uncovering Genetic Rescue and Functional Rebalancing in Telomeropathies Through Genome Editing and High-Resolution Screening (REBALANCE)

  Genome Research Limited Lbg· Saffron Walden, United Kingdom· EU contribution €2,496,154· until Dec 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  GENOME ENGINEERING OF MACROPHAGES TO MEDIATE REGENERATION OF THE FIBROTIC LUNG (BREATH)

  Medizinische Hochschule Hannover· Hannover, Germany· EU contribution €9,988,380· until Sept 2030· 8 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Determining the mechanistic role of gremlin 1 in the profibrotic activation of monocyte-derived macrophages and in the pathogenesis of idiopathic pulmonary fibrosis (IPF-MDM-GREMLIN)

  University College Dublin, National University of Ireland, Dublin· Dublin, Ireland· EU contribution €268,569· until Jul 2028

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  A peptide targeting p21-CDK4 interaction for treatment of pulmonary fibrosis (FibroPep)

  Weizmann Institute of Science· Rehovot, Israel· EU contribution €150,000· until Dec 2027

10 of 59 running projects, newest first. Listed amounts together: US$24.3m + €37.3m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for IPF

  NCT05016817· The Foundation for Orthopaedics and Regenerative Medicine· Updated 20 Oct 2026

  “Inadequate treatment response observed in preliminary data did not justify enrolling further study participants”Registry text, quoted unchanged. Source

• Terminated

  Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

  NCT06097260· Pliant Therapeutics, Inc.· Updated 5 Aug 2026

  “DSMB recommendation”Registry text, quoted unchanged. Source

• Terminated

  Effect of CPAP on Abnormal Gastroesophageal Reflux and Lung Inflammation in IPF

  NCT05359965· University of Arizona· Updated 9 Mar 2026

  “Lack of enrollment”Registry text, quoted unchanged. Source

• Terminated

  To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF

  NCT05497284· Novartis Pharmaceuticals· Updated 13 Jan 2026

  “Sponsor Decision”Registry text, quoted unchanged. Source

• Suspended

  Evaluation of Oral ORIN1001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

  NCT04643769· Orinove, Inc.· Updated 30 May 2025

  “Partnership activities ongoing”Registry text, quoted unchanged. Source

• Withdrawn

  A Study to Investigate Leramistat in Patients With IPF

  NCT05951296· Modern Biosciences Ltd· Updated 9 Apr 2025

  “Due to slow initial recruitment and a lack of confidence in our ability to complete recruitment within the forecasted timeframe.”Registry text, quoted unchanged. Source

• Terminated

  A Study of Patients With Chronic Disease

  NCT04263727· Target PharmaSolutions, Inc.· Updated 3 Apr 2025

  “Sponsor decision to terminate study”Registry text, quoted unchanged. Source

• Withdrawn

  A Phase 2 Study to Evaluate Safety and Efficacy of AMB-05X in Subjects With Idiopathic Pulmonary Fibrosis

  NCT05349760· AmMax Bio, Inc.· Updated 19 Jan 2023

  “to focus resources on other studies”Registry text, quoted unchanged. Source

• Withdrawn

  Inhaled NAC in Treatment of IPF

  NCT03720483· University of Colorado, Denver· Updated 8 Jun 2021

  “The study encountered challenges during startup due to the COVID-19 epidemic and was withdrawn.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard Treatment

  NCT07926321· Boehringer Ingelheim· Source

• SUPPORT-T in Patients With Progressive Pulmonary Fibrosis and Their Caregivers

  NCT07269262· Medical University of South Carolina· Source

• A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

  NCT06238622· Boehringer Ingelheim· Source

• A Phase IIb Study to Evaluate AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)

  2025-525016-41-00· AstraZeneca AB· Source

• A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment

  NCT07036523· Boehringer Ingelheim· Source

• Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease

  NCT06714123· Vejle Hospital· Source

• Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

  NCT07441408· Bristol-Myers Squibb· Source

• A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

  NCT07652658· AstraZeneca· Source

• Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 Trial

  NCT07482917· Hospital de Granollers· Source

• Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial

  NCT07486206· Hospital de Granollers· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 19
• Organoids 4
• Mendelian Randomization Analysis 20
• CRISPR-Cas Systems 4
• Gene Expression Profiling 50
• Sequence Analysis, RNA 4
• Whole Genome Sequencing 2
• Exome Sequencing 2
• Proteomics 21
• Metabolomics 10
• Mass Spectrometry 1
• Flow Cytometry 3
• Immunohistochemistry 5
• Liquid Biopsy 1
• Positron-Emission Tomography 3
• Magnetic Resonance Imaging 4
• Machine Learning 28
• Deep Learning 9
• Cohort Studies 38
• Genome-Wide Association Study 19

• Telomere dysfunction and mucociliary impairment drive idiopathic pulmonary fibrosis susceptibility: insights from a Sardinian whole-exome study.

  BMJ Open Respir Res, Jul 2026

• Hypertension in idiopathic pulmonary fibrosis: evidence of immune and genetic links from clinical and genomic analyses.

  Respir Res, Dec 2025

See which targets of this disease your abstract mentions, and go to the people working on them.